Navigation Oskar-Bordeaux par Etablissement "INRIA"
Voici les éléments 1-20 de 36
-
ChatGPT et au-delà avec l’intelligence artificielle en santé : des leçons à tirer
(Revue du Rhumatisme. vol. 91, n° 1, pp. 12-15, 2024-01-01)Article de revue -
CASCADE protocol: exploring current viral and host characteristics, measuring clinical and patient-reported outcomes, and understanding the lived experiences and needs of individuals with recently acquired HIV infection through a multicentre mixed-methods observational study in Europe and Canada.
(BMJ Open. vol. 13, n° 5, pp. e070837, 2023-05-11)Article de revueLibre accès -
Leveraging Contact Network Information in Clustered Randomized Studies of Contagion Processes.
(Observational Studies. vol. 9, n° 2, pp. 157-175, 2023)Article de revueLibre accès -
More than shots in the dark: driving vaccine efficacy in cirrhosis.
(Gut, 2023-06-07)Article de revue -
Contribution of alcohol use in HIV/hepatitis C virus co-infection to all-cause and cause-specific mortality: A collaboration of cohort studies.
(Journal of Viral Hepatitis. vol. 30, n° 9, pp. 775-786, 2023-06-20)Article de revueLibre accès -
CytOpT: Optimal transport with domain adaptation for interpreting flow cytometry data
(Annals of Applied Statistics. vol. 17, n° 2, pp. 1086-1104, 2023-06-01)Article de revueLibre accès -
Estimating the population effectiveness of interventions against COVID-19 in France: A modelling study
(Epidemics. vol. 46, pp. 100744, 2024-03-01)Article de revueLibre accès -
All-cause hospitalisation among people living with HIV according to gender, mode of HIV acquisition, ethnicity, and geographical origin in Europe and North America: findings from the ART-CC cohort collaboration
(Lancet Public Health. vol. 8, n° 10, pp. 776-787, 2023-10)Article de revueLibre accès -
A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials
(EClinicalMedicine. vol. 65, pp. 102283, 2023-11)Article de revueLibre accès -
All-cause mortality before and after DAA availability among people living with HIV and HCV: An international comparison between 2010 and 2019
(International Journal of Drug Policy. vol. 124, pp. 104311, 2024-01-06)Article de revue -
Estimation of Improvements in Mortality in Spectrum Among Adults With HIV Receiving Antiretroviral Therapy in High-Income Countries
(Journal of Acquired Immune Deficiency Syndromes - JAIDS. vol. 95, n° 1S, pp. e89-e96, 2024-01-01)Article de revueLibre accès -
Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies
(Lancet HIV. vol. 11, n° 2, pp. e106-e116, 2024-01-12)Article de revue -
CRP under 130 mg/L rules out the diagnosis of Legionella pneumophila serogroup 1 (URINELLA Study)
(European Journal of Clinical Microbiology & Infectious Diseases, 2024-03-26)Article de revueLibre accès -
Evaluating the Use of Generalized Dynamic Weighted Ordinary Least Squares for Individualized Hiv Treatment Strategies
(Annals of Applied Statistics. vol. 17, n° 3, pp. 2432-2451, 2023-09)Article de revueLibre accès -
Post-clustering difference testing: valid inference and practical considerations
(Computational Statistics and Data Analysis)Article de revueLibre accès -
Statistical classification of treatment responses in mouse clinical trials for stratified medicine in oncology drug discovery
(Scientific Reports. vol. 14, n° 1, pp. 934, 2024-01-09)Article de revueLibre accès -
Time to treatment initiation and HIV viral suppression in people diagnosed with HIV-1 during COVID-19 pandemic in ex-Aquitaine, France (ANRS CO3 AQUIVIH-NA Cohort-QuAliCOV Study)
(Journal of Acquired Immune Deficiency Syndromes - JAIDS, 2023-09-28)Article de revue -
Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL Collaboration and the Antiretroviral Therapy Cohort Collaboration
(The Lancet HIV. vol. 10, n° 11, pp. e723-e732, 2023-11)Article de revue -
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone
(Lancet Global Health. vol. 11, n° 11, pp. e1743-e1752, 2023-11)Article de revueLibre accès -
A vaccine targeting antigen-presenting cells through CD40 induces protective immunity against Nipah disease
(Cell Reports Medicine. vol. 5, n° 3, pp. 101467, 2024-03-19)Article de revueLibre accès